Improving the Armamentarium of PI3K Inhibitors with Isoform-Selective Agents: A New Light in the Darkness.
Sign Up to like & getrecommendations! Published in 2017 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-17-0500
Abstract: Excitement and drug-development efforts aimed at targetable genetic aberrations in the PI3K/AKT/mTOR pathway have declined due to the limited clinical performance of these inhibitors as monotherapies. New, more isoform-selective treatments, such as taselisib, promise to… read more here.
Keywords: inhibitors isoform; armamentarium pi3k; improving armamentarium; isoform selective ... See more keywords